New lung cancer trial to help predict relapse.

[2greys]

A new international Phase 3 clinical trial coordinated by Crick Senior Group Leader and Cancer Research UK’s chief clinician, Charles Swanton, will use personalised detection tests to look for the earliest signs of relapse in over 300 patients with lung cancer.

The MERMAID-1 trial is a collaboration between the pharmaceutical company, AstraZeneca, and oncology genomics company, ArcherDX.

Researchers will recruit around 330 patients with early-stage non-small cell lung cancer who have had their primary tumour removed in surgery across over 200 international hospital sites. The team will use a personalised monitoring approach co-developed at the Crick for each patient to look for the earliest signs of relapse, specifically, tumour mutations in DNA in their blood that have been released by the tumour, which is called circulating tumour DNA. These tests are being developed by ArcherDX.

crick.ac.uk/news/2020-05-26...

[Picasso7]

How can I find out ore about this . I am recently diagnosed with lung cancer stage 2 band live in Kuala Lumpur Malaysia . I believe this trial is international .

Looking forward to hearing from you

Marguerite

[2greys in reply to Picasso7]

You might want send an email enquiry to the project leader:

[e-mail]

[Picasso7 in reply to 2greys]

Thank you so much .

I had asked my Oncologist. Dr Tho Lye Mum here in KL but I didn’t get a reply .

Thanks again

Marguerite